Literature DB >> 20093487

Lack of a major role of Staphylococcus aureus Panton-Valentine leukocidin in lower respiratory tract infection in nonhuman primates.

Randall J Olsen1, Scott D Kobayashi, Ara A Ayeras, Madiha Ashraf, Shawna F Graves, Willie Ragasa, Tammy Humbird, Jamieson L Greaver, Constance Cantu, Jody L Swain, Leslie Jenkins, Terry Blasdel, Philip T Cagle, Donald J Gardner, Frank R DeLeo, James M Musser.   

Abstract

Panton-Valentine leukocidin (PVL) is a two-component cytolytic toxin epidemiologically linked to community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections, including serious invasive infections caused by the epidemic clone referred to as strain USA300. Although PVL has long been known to be a S. aureus virulence molecule in vitro, the relative contribution of this leukotoxin to invasive CA-MRSA infections such as pneumonia remains controversial. We developed a nonhuman primate model of CA-MRSA pneumonia and used it to test the hypothesis that PVL contributes to lower respiratory tract infections caused by S. aureus strain USA300. The lower respiratory tract disease observed in this monkey model mimicked the clinical and pathological features of early mild to moderate S. aureus pneumonia in humans, including fine-structure histopathology. In this experiment using a large sample of monkeys and multiple time points of examination, no involvement of PVL in virulence could be detected. Compared with the wild-type parental USA300 strain, the isogenic PVL deletion-mutant strain caused equivalent lower respiratory tract pathology. We conclude that PVL does not contribute to lower respiratory tract infection in this nonhuman primate model of human CA-MRSA pneumonia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20093487      PMCID: PMC2832154          DOI: 10.2353/ajpath.2010.090960

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

Review 1.  Leukocidal toxins of staphylococci.

Authors:  S Szmigielski; G Prévost; H Monteil; D A Colin; J Jeljaszewicz
Journal:  Zentralbl Bakteriol       Date:  1999-04

2.  From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus--Minnesota and North Dakota, 1997-1999.

Authors: 
Journal:  JAMA       Date:  1999 Sep 22-29       Impact factor: 56.272

3.  Evolutio of natural resistance to the newer penicillins.

Authors:  G T STEWART; R J HOLT
Journal:  Br Med J       Date:  1963-02-02

4.  Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity.

Authors:  Juan E Moyron-Quiroz; Javier Rangel-Moreno; Kim Kusser; Louise Hartson; Frank Sprague; Stephen Goodrich; David L Woodland; Frances E Lund; Troy D Randall
Journal:  Nat Med       Date:  2004-08-15       Impact factor: 53.440

5.  Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes.

Authors:  John S Francis; Meg C Doherty; Uri Lopatin; Cecilia P Johnston; Gita Sinha; Tracy Ross; Mian Cai; Nadia N Hansel; Trish Perl; John R Ticehurst; Karen Carroll; David L Thomas; Eric Nuermberger; John G Bartlett
Journal:  Clin Infect Dis       Date:  2004-12-07       Impact factor: 9.079

6.  Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients.

Authors:  Yves Gillet; Bertrand Issartel; Philippe Vanhems; Jean-Christophe Fournet; Gerard Lina; Michèle Bes; François Vandenesch; Yves Piémont; Nicole Brousse; Daniel Floret; Jerome Etienne
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

7.  Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.

Authors:  G Lina; Y Piémont; F Godail-Gamot; M Bes; M O Peter; V Gauduchon; F Vandenesch; J Etienne
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

8.  Genome and virulence determinants of high virulence community-acquired MRSA.

Authors:  Tadashi Baba; Fumihiko Takeuchi; Makoto Kuroda; Harumi Yuzawa; Ken-ichi Aoki; Akio Oguchi; Yoshimi Nagai; Natsuko Iwama; Kazuyuki Asano; Timothy Naimi; Hiroko Kuroda; Longzhu Cui; Kenji Yamamoto; Keiichi Hiramatsu
Journal:  Lancet       Date:  2002-05-25       Impact factor: 79.321

9.  Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.

Authors:  Thomas W Geisbert; Joan B Geisbert; Anders Leung; Kathleen M Daddario-DiCaprio; Lisa E Hensley; Allen Grolla; Heinz Feldmann
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

Review 10.  The changing epidemiology of Staphylococcus aureus?

Authors:  H F Chambers
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

View more
  25 in total

1.  Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxins.

Authors:  Benoît-Joseph Laventie; Hendrik Jan Rademaker; Maher Saleh; Ernie de Boer; Rick Janssens; Tristan Bourcier; Audrey Subilia; Luc Marcellin; Rien van Haperen; Joyce H G Lebbink; Tao Chen; Gilles Prévost; Frank Grosveld; Dubravka Drabek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

Review 2.  Virulence strategies of the dominant USA300 lineage of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

Authors:  Lance R Thurlow; Gauri S Joshi; Anthony R Richardson
Journal:  FEMS Immunol Med Microbiol       Date:  2012-03-05

Review 3.  The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections.

Authors:  Gordon Y C Cheung; Michael Otto
Journal:  Expert Opin Ther Targets       Date:  2012-04-25       Impact factor: 6.902

Review 4.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

Review 5.  The bicomponent pore-forming leucocidins of Staphylococcus aureus.

Authors:  Francis Alonzo; Victor J Torres
Journal:  Microbiol Mol Biol Rev       Date:  2014-06       Impact factor: 11.056

6.  Presence of genes encoding panton-valentine leukocidin is not the primary determinant of outcome in patients with hospital-acquired pneumonia due to Staphylococcus aureus.

Authors:  Batu K Sharma-Kuinkel; Sun H Ahn; Thomas H Rude; Yurong Zhang; Steven Y C Tong; Felicia Ruffin; Fredric C Genter; Kevin R Braughton; Frank R Deleo; Steven L Barriere; Vance G Fowler
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

7.  Community-acquired necrotizing pneumonia due to methicillin-sensitive Staphylococcus aureus secreting Panton-Valentine leukocidin: a review of case reports.

Authors:  Lukas Kreienbuehl; Emmanuel Charbonney; Philippe Eggimann
Journal:  Ann Intensive Care       Date:  2011-12-22       Impact factor: 6.925

8.  Panton-Valentine leukocidin antibodies for the treatment of MRSA skin infections?

Authors:  Michael Otto
Journal:  Expert Rev Anti Infect Ther       Date:  2011-04       Impact factor: 5.091

9.  Seasonal H3N2 influenza A virus fails to enhance Staphylococcus aureus co-infection in a non-human primate respiratory tract infection model.

Authors:  Scott D Kobayashi; Randall J Olsen; Rachel A LaCasse; David Safronetz; Madiha Ashraf; Adeline R Porter; Kevin R Braughton; Friederike Feldmann; Dawn R Clifton; John C Kash; John R Bailey; Donald J Gardner; Michael Otto; Douglas L Brining; Barry N Kreiswirth; Jeffrey K Taubenberger; Michael J Parnell; Heinz Feldmann; James M Musser; Frank R DeLeo
Journal:  Virulence       Date:  2013-10-08       Impact factor: 5.882

Review 10.  The effects of Staphylococcus aureus leukotoxins on the host: cell lysis and beyond.

Authors:  Pauline Yoong; Victor J Torres
Journal:  Curr Opin Microbiol       Date:  2013-02       Impact factor: 7.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.